Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R. Mato, Wojciech Jurczak, Krish Patel et al.|New England Journal of Medicine|2023Cited by 213
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN studyKrish Patel, P. L. Zinzani, Julie M Vose et al.|Blood Advances|2026Cited by 1